explore -WSS

explore

author：comprehensive 2025-08-26 01:32:37 - browse：23

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： The high cost of giving birth even with insurance
Next article： Second xenotransplant done with gene

hotspot

WSS

Steward Health Care Massachusetts hospitals face fiscal disaster

President Biden's budget: Here's what you might have missed

Second xenotransplant done with gene

Medical student insurance fails on mental health care coverage

John Green on his newest strategy for fighting tuberculosis

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

focus

explore

explore

Moonlake's readout produced a cash windfall. Risks remain

Thermo Fisher plant for manufacturing gene therapies to expand

DIEP, the 'gold standard' of breast reconstruction, is under threat

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Malaria cases in Florida and Texas: Here’s what you need to know

Lasker Awards 2023: Winners in biomedical research

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

CDC's new outbreak response network to include Northeastern

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Virtual Event: Putting AI to the Test

knowledge

Readout Newsletter: Bristol, Sangamo, Gilead, and more

HHS secretary Becerra pressed on Change HealthCare cyberattack

It's been 20 years since Dolly the sheep. Where's my clone?

Microbiome research is starting to find links to chronic diseases

Male and female sex labels in research insufficient, scientists say

Why scientists need input from humanists on sensitive research

focus

hotspot

focus

explore